A series of OA-tacrine hybrids with the alkylamine linker was designed, synthesized, and evaluated as effective cholinesterase inhibitors for the treatment of Alzheimer’s disease (AD). Here, BCHE is linked to early-onset autosomal dominant Alzheimer disease.